Table 1.

Polymorphisms in CYP1B1 and associations with invasive breast cancer

No. invasive cases (%)
No. controls (%)
OR* (95% CI)*
Ptrend
n = 1655n = 1470
rs163077
CC862 (52.4)778 (53.4)1.00 (Reference)
CT595 (36.2)527 (36.2)1.00 (0.86-1.16)
TT121 (7.4)98 (6.7)1.08 (0.81-1.44)0.73
rs163086
CC1007 (61.2)883 (60.6)1.00 (Reference)
CT528 (32.1)470 (32.3)0.99 (0.85-1.15)
TT63 (3.8)75 (5.2)0.74 (0.52-1.04)0.24
rs9341266
CC1487 (90.2)1333 (91.1)1.00 (Reference)
CT128 (7.9)92 (6.3)1.27 (0.96-1.68)
TT8 (0.5)2 (0.1)4.36 (0.92-20.72)0.021
rs162562
AA969 (58.9)871 (59.8)1.00 (Reference)
AC556 (33.8)476 (32.7)1.03 (0.89-1.21)
CC81 (4.9)84 (5.8)0.86 (0.62-1.18)0.75
rs1800440
AA1070 (64.9)934 (63.8)1.00 (Reference)
AG483 (29.3)430 (29.4)1.00 (0.86-1.17)
GG65 (3.9)53 (3.6)1.08 (0.74-1.57)0.81
rs162557
CC901 (54.8)837 (57.5)1.00 (Reference)
CT609 (37.0)489 (33.6)1.14 (0.98-1.33)
TT88 (5.4)98 (6.7)0.82 (0.61-1.11)0.80
rs162556
TT421 (25.6)392 (26.9)1.00 (Reference)
CT829 (50.4)727 (49.9)1.05 (0.89-1.25)
CC354 (21.5)311 (21.4)1.05 (0.86-1.29)0.61
rs10175368
GG836 (50.7)765 (52.3)1.00 (Reference)
AG660 (40.1)552 (37.7)1.09 (0.94-1.26)
AA122 (7.4)114 (7.8)0.98 (0.75-1.29)0.58
  • * ORs adjusted for reference age (categorical) and state of residence.

  • Tests for trend in breast cancer risk for each SNP were conducted by inclusion of an indicator term representing the number of minor alleles (0, 1, 2).

  • Differences between the total numbers of cases and controls and frequencies shown in the table are due to missing genotype data.